Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity
Background: Fc gamma receptor 3A (FCGR3A) encodes a receptor for the Fc portion of immunoglobulin G, which plays a significant role in the immune response. However, the role of FCGR3A in cancers remains unclear. This study aimed to visualize the prognostic landscape of FCGR3A in pan-cancer and inves...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.900699/full |
| _version_ | 1811339917436911616 |
|---|---|
| author | Lilin Li Zijian Huang Kunpeng Du Xiang Liu Chunhui Li Duanyu Wang Yangfeng Zhang Changqian Wang Jiqiang Li Jiqiang Li |
| author_facet | Lilin Li Zijian Huang Kunpeng Du Xiang Liu Chunhui Li Duanyu Wang Yangfeng Zhang Changqian Wang Jiqiang Li Jiqiang Li |
| author_sort | Lilin Li |
| collection | DOAJ |
| description | Background: Fc gamma receptor 3A (FCGR3A) encodes a receptor for the Fc portion of immunoglobulin G, which plays a significant role in the immune response. However, the role of FCGR3A in cancers remains unclear. This study aimed to visualize the prognostic landscape of FCGR3A in pan-cancer and investigate the relationship between FCGR3A expression and tumor microenvironment.Method: Based on the TCGA database, GTEx database, and GDSC database, we analyzed the expression of FCGR3A in pan-cancers and adjacent normal tissues and its relationship with prognosis, immune cells infiltration, immune-related genes, DNA mismatch repair (MMR) genes, DNA methylation, and drugs sensitivity. The gene alteration frequency of FCGR3A was acquired on the cBioportal website. Moreover, we constructed PPI networks, performed GO and KEGG analysis to illustrate the function, and signaling pathways of FCGR3A-related genes, and conducted gene set enrichment analysis (GSEA) of FCGR3A to further explore its potential biological functions.Result: The differential analysis results of the publicly available databases showed that FCGR3A was generally highly expressed in pan-cancer. Survival analysis revealed that FCGR3A predominated as a risk prognostic factor in most cancers. Additionally, the expression of FCGR3A was confirmed to be associated with several immune cells infiltration, multiple immune checkpoint genes, and DNA mismatch repair genes expression in generalized carcinoma. We also identified a negative correlation between FCGR3A and DNA methylation levels. Through GO/KEGG and GESA, we found that FCGR3A was involved in many pathologic and physiological processes, and was most closely related to tumor immune-related pathways. Drug sensitivity analysis showed that higher FCGR3A expression predicts a low IC50 value for the vast majority of drugs.Conclusions: FCGR3A may be an immune-oncogenic molecule that correlates with tumor immune infiltration levels and affects drug sensitivity, thus it can be served as a promising biomarker for cancer detection, prognosis, therapeutic design, and follow-up. |
| first_indexed | 2024-04-13T18:33:34Z |
| format | Article |
| id | doaj.art-bddc1e10fbbb4758b94ff46b46ed0594 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T18:33:34Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-bddc1e10fbbb4758b94ff46b46ed05942022-12-22T02:34:59ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-05-011310.3389/fphar.2022.900699900699Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor ImmunityLilin Li0Zijian Huang1Kunpeng Du2Xiang Liu3Chunhui Li4Duanyu Wang5Yangfeng Zhang6Changqian Wang7Jiqiang Li8Jiqiang Li9Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, ChinaDepartment of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, ChinaBackground: Fc gamma receptor 3A (FCGR3A) encodes a receptor for the Fc portion of immunoglobulin G, which plays a significant role in the immune response. However, the role of FCGR3A in cancers remains unclear. This study aimed to visualize the prognostic landscape of FCGR3A in pan-cancer and investigate the relationship between FCGR3A expression and tumor microenvironment.Method: Based on the TCGA database, GTEx database, and GDSC database, we analyzed the expression of FCGR3A in pan-cancers and adjacent normal tissues and its relationship with prognosis, immune cells infiltration, immune-related genes, DNA mismatch repair (MMR) genes, DNA methylation, and drugs sensitivity. The gene alteration frequency of FCGR3A was acquired on the cBioportal website. Moreover, we constructed PPI networks, performed GO and KEGG analysis to illustrate the function, and signaling pathways of FCGR3A-related genes, and conducted gene set enrichment analysis (GSEA) of FCGR3A to further explore its potential biological functions.Result: The differential analysis results of the publicly available databases showed that FCGR3A was generally highly expressed in pan-cancer. Survival analysis revealed that FCGR3A predominated as a risk prognostic factor in most cancers. Additionally, the expression of FCGR3A was confirmed to be associated with several immune cells infiltration, multiple immune checkpoint genes, and DNA mismatch repair genes expression in generalized carcinoma. We also identified a negative correlation between FCGR3A and DNA methylation levels. Through GO/KEGG and GESA, we found that FCGR3A was involved in many pathologic and physiological processes, and was most closely related to tumor immune-related pathways. Drug sensitivity analysis showed that higher FCGR3A expression predicts a low IC50 value for the vast majority of drugs.Conclusions: FCGR3A may be an immune-oncogenic molecule that correlates with tumor immune infiltration levels and affects drug sensitivity, thus it can be served as a promising biomarker for cancer detection, prognosis, therapeutic design, and follow-up.https://www.frontiersin.org/articles/10.3389/fphar.2022.900699/fullpan-cancer analysisFCGR3Atumor biomarkerimmune infiltrationtumor microenvironmentprognosis |
| spellingShingle | Lilin Li Zijian Huang Kunpeng Du Xiang Liu Chunhui Li Duanyu Wang Yangfeng Zhang Changqian Wang Jiqiang Li Jiqiang Li Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity Frontiers in Pharmacology pan-cancer analysis FCGR3A tumor biomarker immune infiltration tumor microenvironment prognosis |
| title | Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity |
| title_full | Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity |
| title_fullStr | Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity |
| title_full_unstemmed | Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity |
| title_short | Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity |
| title_sort | integrative pan cancer analysis confirmed that fcgr3a is a candidate biomarker associated with tumor immunity |
| topic | pan-cancer analysis FCGR3A tumor biomarker immune infiltration tumor microenvironment prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.900699/full |
| work_keys_str_mv | AT lilinli integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT zijianhuang integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT kunpengdu integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT xiangliu integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT chunhuili integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT duanyuwang integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT yangfengzhang integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT changqianwang integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT jiqiangli integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity AT jiqiangli integrativepancanceranalysisconfirmedthatfcgr3aisacandidatebiomarkerassociatedwithtumorimmunity |